- Home
- TENB vs RARE Comparison
TENB vs RARE Comparison
Compare TENB & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENB | RARE |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 2018 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TENB | RARE |
|---|---|---|
| Price | $17.78 | $22.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 19 |
| Target Price | $35.53 | ★ $66.32 |
| AVG Volume (30 Days) | ★ 3.1M | 2.2M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.41 | 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $900,021,000.00 | $673,000,000.00 |
| Revenue This Year | $9.37 | $17.23 |
| Revenue Next Year | $7.04 | $36.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.68 | ★ 20.13 |
| 52 Week Low | $19.15 | $18.41 |
| 52 Week High | $39.13 | $43.51 |
Technical Indicators
Market Signals| Indicator | TENB | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 27.10 | 45.53 |
| Support Level | N/A | $22.00 |
| Resistance Level | $23.33 | $25.46 |
| Average True Range (ATR) | 1.40 | 1.40 |
| MACD | -0.20 | 0.06 |
| Stochastic Oscillator | 0.80 | 52.21 |
Price Performance
Historical ComparisonAbout TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.